Heterogeneity in recent-onset type 1 diabetes - a clinical trial perspective

Diabetes/Metabolism Research and Reviews

Volumn 31, Issue 6, 2015, Pages 588-594

  Bollyky, Jennifer B ^a   Xu, Ping ^b   Butte, Atul J ^a   Wilson, Darrell M ^a   Beam, Craig A ^c   Greenbaum, Carla J ^d  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c WESTERN MICHIGAN UNIVERSITY HOMER STRYKER MD SCHOOL OF MEDICINE   (United States)

^d BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

C peptide; Type 1 diabetes clinical trials; Type 1 diabetes TrialNet

Indexed keywords

ABATACEPT; AUTOANTIBODY; C PEPTIDE; CANAKINUMAB; DACLIZUMAB; GLUCOSE; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; HEMOGLOBIN A1C; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; INSULINOMA ANTIGEN 2 ANTIBODY; MYCOPHENOLATE MOFETIL; PANCREAS ISLET CELL ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CHILD; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LEUKOCYTE COUNT; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); AGE; BLOOD; CHILDHOOD OBESITY; CLINICAL TRIAL; COHORT ANALYSIS; COMPLICATION; IMMUNOLOGY; ITALY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NORTH AMERICA; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AUTOANTIBODIES; BIOMARKERS; BODY MASS INDEX; C-PEPTIDE; CHILD; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; HUMANS; ITALY; LEUKOPENIA; LYMPHOPENIA; MIDDLE AGED; NORTH AMERICA; OBESITY; OVERWEIGHT; PEDIATRIC OBESITY; YOUNG ADULT;

EID: 84941260792     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2643     Document Type: Article

References (13)

1. Pescovitz MD, Greenbaum CJ, Bundy B, et al. B-lymphocyte depletion with rituximab and beta-cell function: two-year results. Diabetes Care 2014; 37(2): 453-459. doi:10.2337/dc13-0626.
2. Orban T, Bundy B, Becker DJ, et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 378(9789): 412-419. doi:10.1016/S0140-6736(11)60886-6.
3. Ludvigsson J, Krisky D, Casas R, et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 2012; 366(5): 433-442. doi:10.1056/NEJMoa1107096.
4. Gottlieb PA, Quinlan S, Skyler JS, et al. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new-onset type 1 diabetes. Diabetes Care 2010; 33(4): 826-832. doi:10.2337/dc09-1349.
5. Moran A, Bundy B, Becker DJ, et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 2013; 381(9881): 1905-1915. doi:10.1016/S0140-6736(13)60023-9.
6. Greenbaum CJ, Beam CA, Boulware D, et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 2012; 61(8): 2066-2073. doi:10.2337/db11-1538.
7. Barker A, Lauria A, Schloot N, et al. Age-dependent decline of beta-cell function in type 1 diabetes after diagnosis: a multi-centre longitudinal study. Diabetes Obes Metab 2014; 16(3): 262-267. doi:10.1111/dom.12216.
8. Ludvigsson J, Carlsson A, Deli A, et al. Decline of C-peptide during the first year after diagnosis of type 1 diabetes in children and adolescents. Diabetes Res Clin Pract 2013; 100(2): 203-209. doi:10.1016/j.diabres.2013.03.003.
9. Centers for Disease Control and Prevention/National Center for Health Statistics, 1994. Plan and operation of the third National Health and Nutrition Examination Survey, 1988-94.
10. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003; 26(3): 832-836. doi:10.2337/diacare.26.3.832.
11. Lachin JM, McGee P, Palmer JP, DCCT/EDIC Research Group. Impact of C-peptide preservation on metabolic and clinical outcomes in the diabetes control and complications trial. Diabetes 2014; 63(2): 739-748. doi:10.2337/db13-0881.
12. Valle A, Giamporcaro GM, Scavini M, et al. Reduction of circulating neutrophils precedes and accompanies type 1 diabetes. Diabetes 2013; 62(6): 2072-2077. doi:10.2337/db12-1345.
13. Redondo MJ, Rodriguez LM, Escalante M, et al. Beta cell function and BMI in ethnically diverse children with newly diagnosed autoimmune type 1 diabetes. Pediatr Diabetes 2012; 13(7): 564-571. doi:10.1111/j.1399-5448.2012.00875.x.